CD274 and gastric cancer: Further, investigations in the phase 3 KEYNOTE-061 study suggested that the efficacy of pembrolizumab as a second-line treatment in previously treated patients with GC/GEJC may depend on the degree of expression of tumour programmed death ligand 1 (PD-L1) (13).